After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.
JNJ’4496 demonstrated an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.
Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.
Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.
Oncology experts recap their key takeaways from the 2025 ESMO Gastrointestinal Cancers Congress.
Clinical Outcomes with Epcoritamab in Relapsed/Refractory 3L+ DLBCL Review efficacy and safety data, including extended follow-up data from the EPCORE ® NHL-1 trial, which evaluated…
Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.
Bladder Cancer Landscape
The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.
ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.
